- R&D Network
-
Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.
R&D Network
Hanmi R&D network consists of 6 sites creating a synergistic effect. Fully integrated 3 R&D Centers in Dongtan (Korea), Paltan (Korea), and Beijing (China) focus on new drug discovery and formulation research. Global Business Division and New Product Development Division in our headquarters performs clinical research, regulatory affairs and licensing business. In addition, there are two process development research sites for biologics and chemical APIs.
Hanmi R&D Center
Global Business Division and New Product Development Division (Headquarters)
Pharmaceutical R&D Team
Bioprocess Development Team
Hanmi Fine Chemical R&D Center
NAME | Location | Major Fields of Research | Number of Personnel |
---|---|---|---|
Hanmi R&D Center | Dongtan, Gyeonggi-do in Korea | New biological drugs, New chemical drugs | 150+ |
Global Business Division and New Product Development Division (Headquarters) | Songpa-gu, Seoul in Korea | Clinical studies, Regulatory affairs, Licensing in & out | 110+ |
Pharmaceutical R&D Team | Paltan, Gyeonggi-do in Korea | New medicines, Drug transfer platform technology | 60+ |
Bioprocess Development Team | Pyeongtaek, Gyeonggi-do in Korea | Manufacturing and development of recombinant protein products | 50+ |
Hanmi Fine Chemical R&D Center | Sihwa, Gyeonggi-do in Korea | Mass production of active pharmaceutical ingredients | 50+ |
Beijing Hanmi R&D Center | Beijing in China | New bispecific antibodies | 120+ |